Vaxxinity offers a COVID-19 antibody test based on its synthetic peptide technology platform.  This highly specific and sensitive IgG ELISA can help to identify those who have been exposed to COVID-19 and developed antibodies.  The immunoassay kit comes with 2 96-well test plates that can run 10μL samples of serum or plasma on a standard ELISA plate reader.

What is an antibody test?

When a virus infects a person, or when a vaccine is administered, the immune system produces antibodies specific to that virus to fight infection.  A COVID-19 antibody test, using a small sample of blood, detects the antibodies directed against SARS-CoV-2.  Vaxxinity’s parent company United Biomedical, Inc. (UBI) has developed a COVID-19 antibody test called the UBI® SARS-CoV-2 ELISA, made in New York, which Vaxxinity has commercialized.

Our antibody test is useful, fast and scalable.

Ideal for large scale screenings and epidemiological studies, or as a complement to vaccination or PCR testing, our SARS-CoV-2 ELISA can yield thousands of results per day in a properly equipped and qualified serology lab.  Antibodies may be detected starting 10 days after disease onset, and remain in the blood for months.  Thus antibody detection can inform who among a population has had exposure to the virus and developed an immune response.

How has our test been validated?

Vaxxinity’s SARS-CoV-2 ELISA has been validated on over 900 blood samples that were collected and tested in California, Taiwan and China from PCR-positive patients, using pre-COVID-19 serum samples as negative controls.  Specificity validation samples included serum from patients who previously tested positive for other human coronaviruses (e.g., NL63, HKU-1) as well as other infectious diseases (e.g., HIV, HCV, HBV).

How is our test different from a PCR test?

Vaxxinity’s SARS-CoV-2 ELISA has been validated on over 900 blood samples that were collected and tested in California, Taiwan and China from PCR-positive patients, using pre-COVID-19 serum samples as negative controls.  Specificity validation samples included serum from patients who previously tested positive for other human coronaviruses (e.g., NL63, HKU-1) as well as other infectious diseases (e.g., HIV, HCV, HBV).

How can communities test at scale?

We’ve received many inquiries about large scale testing from governments and corporations. Antibody tests can quickly identify who in a population has developed antibodies to SARS-CoV-2 through either natural infection or vaccination.  This can provide leaders, public health officials, and the public with more accurate information about the prevalence of infection and immunity in a given population, which can help to contain community spread.

FDA Emergency Use Authorization (EUA) Issued

FDA issued emergency use authorization (EUA) for the UBI SARS-CoV-2 ELISA kit in January 2021.